ABOUT PHARMACOPEIA Pharmacopeia be committed to unearth and evolving visual therapeutics to address innermost medical requests. The ensemble have a dense portfolio advance toward clinical validation, both against your own and near partner. Pharmacopeia's topmost advanced private program is a dual-acting angiotensin and endothelin receptor antagonist (DARA) all for hypertension and diabetic kidney bacteria for which a Phase 2 clinical try-out is on the go. Other internal proprietary programs address above all immunoregulation. Pharmacopeia's collaborative hard industry individual resulted surrounded by a portfolio that take in two partnered programs now in Phase 2 clinical trial: a CXCR2 antagonist target inveterate obstructive pulmonary disease (COPD) and a p38 MAP kinase inhibitor for inflammatory disease. Three partnered programs in Phase 1 clinical trials target oncology, inflammatory and respiratory diseases. Three inferior partnered compound be in preclinical innovation. Pharmacopeia's established strategic alliances are with Cephalon, GlaxoSmithKline, Organon and Wyeth.
This pinch production, and oral assertion made regarding facts contained here press release, constitute forward-looking statements in the intent of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which put across aim, anticipation, out of stock, aspiration, contingency or in the near future development and/or otherwise are not statements of historical certainty. These statements are accept upon management's current expectations and are problem to jeopardy and uncertainties, fix and unknown, which could incentive actual grades and development to differ materially from those expressed or implied in such statements. These forward- look statements include, but are not settled to, statements in the instruct of the jubilant effecting of Pharmacopeia's strategic implementation, Pharmacopeia's plans to work on PS433540, a stock interviewee from its DARA program, Pharmacopeia's Phase 2 and Phase 1 clinical cram with respect to PS433540, as well as time and programmed outcome of such studies, Pharmacopeia's estimate of the souk opportunity for its product candidate, including PS433540, Pharmacopeia's capacity to elatedly make down below its collaboration with Cephalon, GlaxoSmithKline, Organon and Wyeth, Pharmacopeia's ability to raise its pipeline of novel pills candidates through its personal internally-funded drug revealing programs, third entertainment collaborations and in-licensing, Pharmacopeia's ability to convey to the fore additional income, Pharmacopeia's expectations vis-a-vis the development priority of its collaborator, their ability to successfully develop compounds and its tally of milestone and royalty from the collaborations, Pharmacopeia's anticipated operating results, pecuniary must, liquidity and capital supplies, Pharmacopeia's expectations concerning the trial protection afford via U.S. and cultured government grant dictate, Pharmacopeia's ability to go in pursuit of the development of stunning compounds and other commercial business undersupplied infringing the patent rights of others, additional opposition, and change in monetary goods.
Further information about these and other useful risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K file with the U.S. Securities and Exchange Commission. Pharmacopeia urge you to conscientiously scouting and weigh up the disclosure found in its filings which are unclaimed in the SEC EDGAR database at and from Pharmacopeia at All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the threatening statements incorporated in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements utter singular in pop of of the date of this press release. Pharmacopeia deal with no condition to (and expressly disclaim any such obligation to) publicly update or reword the statements made herein or the risk factor that may describe thereto whether as a corollary of new information, future trial, or otherwise.
Pharmacopeia
More blood pressure blogs
No comments:
Post a Comment